Overview

A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the efficacy and safety of Bendamustine Hydrochloride Injection in subjects with Rituximab-resistant Indolent B-Cell Non-Hodgkin's Lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Treatments:
Bendamustine Hydrochloride